Laurence Buisseret
@laubdh.bsky.social
Medical Oncologist, MD PhD I mother of two 👦👧|#BreastCancer immunotherapy investigator and scientist @JulesBordet Lecturer @ULBruxelles
Cancer du sein : le meilleur dépistage est celui auquel on participe www.lalibre.be/debats/opini...
Cancer du sein : le meilleur dépistage est celui auquel on participe
Détecté précocement, ce cancer se traite de mieux en mieux. Le Mammotest, programme organisé, reste pourtant peu utilisé en Wallonie et à Bruxelles....
lalibre.be
Early stage ER+/HER2- breast cancer patients showed promising clinical responses to neoadjuvant immune-modulating stereotactic body radiotherapy with durvalumab. @alexdecaluwe.bsky.social @laubdh.bsky.social
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial - Nature Medicine
In the randomized phase 2 Neo-CheckRay trial, patients with early-stage ER+HER2− breast cancer received neoadjuvant immune-modulating stereotactic body radiation therapy with or without durvalumab, and with or without the anti-CD73 antibody oleclumab, leading to encouraging clinical responses when durvalumab was added including in patients with PD-L1-negative tumors.
dlvr.it
Can neo-adj RT ⚡️ restore response to ICI in PD-L1-neg ER+ breast cancer? #NeoCheckRay: 3×8 Gy SBRT + anti-PD-L1 showed strong pCR signal in PD-L1 neg . On-treatment biopsies suggest TME reprogramming toward an immune-responsive state. Just published in Nature Medicine ➡️ rdcu.be/fqFY1
@hoperugo.bsky.social is discussing the results of the ROSALINE trial, an IIT sponsored by the Institut Jules Bordet that evaluated ROS1 inhibition with neo-adj endocrine therapy in early ILBC #ESMOBreast25 👏🏻 @aftimosp.bsky.social & Soraia Lobo-Martins
Day 2 of #ESMOBreast25 in Munich. Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC: emiltatug ledadotin and puxitatug samrotecan #ESMOAmbassadors @myesmo.bsky.social
An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example #ESMOAmbassadors @myesmo.bsky.social
What a beautiful presentation @mybsmo by Mireille Langouo about "Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitor". A study conducted @JulesBordet.
Congratulations to all #YoungOncologists - recipients of the #ESMOImmuno24 ESMO Merit Travel Grant 🏆! 📣 Special shout out to ZAYD 🙌 @zaydtippu.bsky.social - who will be presenting our work: "MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery" Go say hi - Poster: 40P!
When @marianabrandao0.bsky.social makes us travel from Geneva #ESMOImmuno24 to Tomorrowland and the Smurf Village throught a brillant discussion of 3 mini orals about treatment strategies for NSCLC patients. Thank you!
Excellent discussion by @marianabrandao0.bsky.social on treatment of patients with #NSCLC #ESMOImmuno24 Insightful perspectives on recent advances!
👏 to J. Stagg & D. Allard for their work revealing ENT1 as a key driver of adenosine-mediated immunosuppression. This finding offers a promising new target to enhance T cell responses against tumors. 👉full study published in Cancer Research @theaacr.bsky.social ➡️ doi.org/10.1158/0008...
Initiation visit this morning at Institut Jules Bordet of the EmpowHER 303 phase 3 study of anti-HER2 bispecific antibody zanidatamab in combination with chemo vs trastuzumab and chemo in HER2+ MBC. clinicaltrials.gov/study/NCT064... #bcsm
